Guotai CSI Bio-medicine ETF

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

159892

512290

159837

159316

159849

588250

159570

159102

588130

United Laboratories has received clearance from China's NMPA to begin clinical trials for its innovative drug TUL108, a broad-spectrum beta-lactamase inhibitor aimed at treating bacterial infections. The drug will be tested in combination with meropenem against drug-resistant pathogens. The U.S. FDA had previously approved the investigational new drug application for TUL108 on January 28, 2026.

PUBT

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

UNITED LAB

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

United Labs says China regulator clears TUL108 injection for clinical trial

159898

562600

510660

A new therapeutic approach for atopic dermatitis is being developed, utilizing a dual mechanism that targets barrier repair through KLK5/7 and inflammation inhibition through IL-13. This first-in-class treatment aims to address the needs of patients with atopic dermatitis. A Phase 2 patient proof-of-concept study focusing on moderate-to-severe cases of atopic dermatitis is planned to commence soon. This study will test the effectiveness of the treatment and its potential benefits for patients.

Unusual Whales

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

iShares US Medical Devices

ChinaAMC SSE Health Care ETF Initiating Fund

Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

ARKG

516500

516930

512010

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

prnewswire

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VG Health

iShares US Pharma

ChinaAMC CSI Biotechnology Theme ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Minsheng Royal CSI Biotechnology Theme ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

E Fund CSI 300 Health Care ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

Health Care Select Sector SPDR

Bosera Hang Seng Health Care ETF(QDII)

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Analyst David Martin PhD of Bloom Burton has reiterated a Buy rating on Microbix Biosystems with a price target of C$0.40. He attributes the recent revenue shortfall to a temporary slowdown in Chinese antigen orders, not structural issues. Demand from non-Chinese customers is increasing, and Microbix has diversified its revenue base, reducing future volatility. This positioning, along with the potential for sales normalization, presents an attractive risk-reward profile.

Tip Ranks

MBX Biosciences

Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand

02359

Wuxi AppTec plans to raise approximately $1 billion through U.S. dollar-settled zero coupon convertible bonds to enhance its capacity and capabilities. The bonds, convertible to shares at an initial price of HK$153, represent about 9.1% of the enlarged H-share capital. The proceeds will be used for global expansion and corporate purposes. Morgan Stanley, Citigroup, and Goldman Sachs are advising on the issuance.

MorningStar

WUXI APPTEC

Hwabao WP CSI Pharmaceuticals ETF

WuXi AppTec

Morgan Stanley

Citigroup

Goldman Sachs

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GS Hldg R

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds

01801

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.

BlackRock, Inc.

iShares Global Healthcare

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

516820

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Penghua CSI HK Connect Health Care Composite ETF

Microbiotica reports positive results for MB097 in advanced melanoma

Ring Therapeutics®, a biotech firm based in Cambridge, Massachusetts, disclosed fresh insights on its Vector Conjugate system and VectorBricks™ in vitro manufacturing technology. The company unveiled this data on May 14, 2026. The innovative platform aims to develop precise medications.

Ring Therapeutics® Presents its Vector Conjugate and VectorBricks™ Manufacturing Platforms at the 29th Annual American Society of Gene & Cell Therapy Conference

Guotai CSI Bio-medicine ETF(512290.SH)

United Labs says China regulator clears TUL108 injection for clinical trial

Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand

Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds